reports
Obalon Announces First Quarter 2021 Financial Results
Obalon Announces First Quarter 2021 Financial Results SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021. On January 19, 2020 the Company signed a definitive agreement for a merger with ReShape Lifesciences Inc. Financial results for the first quarter of 2021 Revenue for the first quarter of 2021 was no...
Obalon Announces Fourth Quarter and Full Year 2020 Financial Results
Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreeme...
Obalon Announces Third Quarter 2020 Financial Results
Obalon Announces Third Quarter 2020 Financial Results SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020 Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the sus...
Obalon Announces Consulting Agreement As Part of Strategy To Seek Cove...
Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those invo...
Obalon Announces Second Quarter 2020 Financial Results
Obalon Announces Second Quarter 2020 Financial Results SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020. Financial results for the second quarter of 2020 Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue...
Obalon Announces First Quarter 2020 Financial Results and Business Upd...
Obalon Announces First Quarter 2020 Financial Results and Business Update SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update. Financial results for the first quarter of 2020 Revenue for the first quarter of 2020 was $0.8 million, compared to $1.8 million for the first quarter of 2019. Net loss...
Obalon Announces Further Impacts Related To Covid-19 Crisis and Curren...
Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ:), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces changes related to the impacts of the Covid-19 crisis and current business environment on its business, organization and strategic options. As previously announced, the overall uncertainty, the rest...
William Plovanic Resigns as President and Chief Executive Officer and ...
William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, the Company’s President and CEO has announced his resignation in order to accept another position. Andy Rasda...
Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health C...
Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA SAN DIEGO, April 28, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity provided further clarification that...
Obalon Engages Canaccord Genuity to Explore Financial and Strategic Al...
Obalon Engages Canaccord Genuity to Explore Financial and Strategic Alternatives SAN DIEGO, March 25, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has decided to explore potential financial and strategic alternatives intended to enhance stockholder value. The Company has engaged Canaccord Genuity LLC as its financial advisor. The overall uncertainty, th...
Obalon Temporarily Suspends New Patient Sales at Its Retail Treatment ...
Obalon Temporarily Suspends New Patient Sales at Its Retail Treatment Centers Due to Coronavirus Pandemic No patients or employees have been found to be symptomatic or positive for the virus, yet patient, employee, and public health remain Obalon’s highest priority SAN DIEGO, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has temporarily suspended sales of...
Obalon Announces Fourth Quarter and Full Year 2019 Financial Results
Obalon Announces Fourth Quarter and Full Year 2019 Financial Results SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2019. “2019 was an eventful year for Obalon as we recapitalized and repositioned the business to efficiently leverage our FDA-approved weight loss system through our new reta...
Obalon Announces Opening of Second Retail Treatment Center in Orange C...
Obalon Announces Opening of Second Retail Treatment Center in Orange County, CA Company continues to execute on its strategy to develop retail treatment sites focused exclusively on treatment with the Obalon Balloon System™ SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has opened its second Company-managed retail treatment center. “We are excited to h...
Obalon Schedules Fourth Quarter and Year-End 2019 Financial Results Co...
Obalon Schedules Fourth Quarter and Year-End 2019 Financial Results Conference Call for February 27, 2020 at 8:30 a.m. Eastern Time SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: ), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to release its fourth quarter and year-end 2019 financial results before the market opens on Thursday, February 27, 2020 and hold a conference call at 8:30 AM Eastern Time (5:30 AM Pacific Time) to discuss...
Obalon Enters into New Stock Purchase Agreement with Lincoln Park Capi...
Obalon Enters into New Stock Purchase Agreement with Lincoln Park Capital Fund SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a new common stock purchase agreement and registration rights agreement (together, the “Agreements”) with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor, for up to $15 million. The ne...
Obalon Enters into a Distribution Agreement for Qatar
Obalon Enters into a Distribution Agreement for Qatar SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:), a vertically integrated weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a one-year agreement with Al Danah Medical Company (“Al Danah”) for distribution of the Obalon Navigation Balloon System in Qatar. Obalon has terminated its agreement with Bader Sultan and Bros. Company for distribution of its prior-generation balloo...
Obalon To Present at Two Upcoming Institutional Investor Conferences
Obalon To Present at Two Upcoming Institutional Investor Conferences SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: ), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that Bill Plovanic, President and Chief Executive Officer, will present corporate overviews at the following investor conferences: Stifel 2019 Healthcare Conference Wed...
Obalon Announces Third Quarter 2019 Financial Results
Obalon Announces Third Quarter 2019 Financial Results SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2019. Third Quarter 2019 highlights: Announced the opening of the first Company-owned retail treatment center, the Obalon Center for Weight Loss in San Diego, CA., and initial patient treatmentsFurther streamlined operatio...
Obalon Announces Clinical Data Set to be Featured During the 36th ASMB...
Obalon Announces Clinical Data Set to be Featured During the 36th ASMBS Annual Meeting at Obesity Week 2019 Real-world results from 222 consecutive patients treated with the Obalon Balloon System demonstrate clinically meaningful weight loss with no serious adverse events SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that clinical data for the Obalon Balloon System used to treat 222 patients a...
Obalon Schedules Third Quarter 2019 Financial Results Conference Call ...
Obalon Schedules Third Quarter 2019 Financial Results Conference Call for November 8, 2019 at 9:00 a.m. Eastern Time SAN DIEGO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to release its third quarter 2019 financial results before the market opens on Friday, November 8, 2019 and hold a conference call at 9:00 AM Eastern Time (6:00 AM Pacific Time) to discuss the Company's financial res...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.